KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Cash from Operations (2017 - 2025)

Historic Cash from Operations for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $118.4 million.

  • Amneal Pharmaceuticals' Cash from Operations fell 1645.15% to $118.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $327.8 million, marking a year-over-year increase of 476.63%. This contributed to the annual value of $295.1 million for FY2024, which is 1460.69% down from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Cash from Operations stood at $118.4 million for Q3 2025, which was down 1645.15% from $83.8 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' Cash from Operations' 5-year high stood at $148.1 million during Q1 2021, with a 5-year trough of -$125.5 million in Q2 2022.
  • Over the past 5 years, Amneal Pharmaceuticals' median Cash from Operations value was $82.4 million (recorded in 2021), while the average stood at $60.9 million.
  • In the last 5 years, Amneal Pharmaceuticals' Cash from Operations tumbled by 14169.8% in 2022 and then skyrocketed by 68313.15% in 2023.
  • Quarter analysis of 5 years shows Amneal Pharmaceuticals' Cash from Operations stood at $63.3 million in 2021, then crashed by 136.82% to -$23.3 million in 2022, then skyrocketed by 683.13% to $135.8 million in 2023, then dropped by 13.06% to $118.1 million in 2024, then grew by 0.32% to $118.4 million in 2025.
  • Its last three reported values are $118.4 million in Q3 2025, $83.8 million for Q2 2025, and $7.4 million during Q1 2025.